In 2013, a FTC rulemaking deemed that the transfers of pharmaceutical patent rights to be reportable assets under the Hart-Scott-Rodino Act (“HSR”).
It has been nearly seven years since the FTC began its fight with Boehringer Ingelheim Pharmaceuticals Inc. to get documents related to Aggrenox.
In a long drawn out legal battle, the FTC has recently announced that it has reached a settlement to resolve the FTC’s antitrust lawsuit against Cephalon.
The FTC has announced that Cardinal Health has agreed to settle charges that it maintained an illegal monopoly over 25 local markets.
Hi-Tech Pharmaceuticals recently won its appeal of a $40 million judgment ordered by a federal district judge regarding the double-blind placebo tests.